Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: A positron emission tomography study using [11C]N-propyl-norapomorphine and [11C] raclopride in baboons

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 80-90

  Narendran, Rajesh ^a,b   Hwang, Dah Ren ^a   Slifstein, Mark ^a   Hwang, Yuying ^a   Huang, Yiyun ^a   Ekelund, Jesper ^a   Guillin, Olivier ^a   Scher, Erica ^a   Martinez, Diana ^a   Laruelle, Marc ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; N PROPYLNORAPOMORPHINE C 11; RACLOPRIDE C 11; TRACER; UNCLASSIFIED DRUG; APOMORPHINE; CARBON; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; N-N-PROPYLNORAPOMORPHINE; PROPYLNORAPOMORPHINE; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BINDING AFFINITY; BINDING SITE; BRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; MALE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; ANIMAL; METABOLISM; PAPIO; SCINTISCANNING;

ANIMALS; APOMORPHINE; BRAIN; CARBON RADIOISOTOPES; DOPAMINE AGONISTS; MALE; PAPIO; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2;

EID: 25644454408     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.090068     Document Type: Article

References (40)

1. Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, et al. (1999) PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32:93-109.
2. Alberts GL, Pregenzer JF, and Im WB (2000) Advantages of heterologous expression of human D2long dopamine receptors in human neuroblastoma SH-SY5Y over human embryonic kidney 293 cells. Br J Pharmacol 131:514-520.
3. Bunney BS, Aghajanian GK, and Roth RH (1973a) Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. Nat New Biol 245:123-125.
4. Bunney BS, Walters JR, Roth RH, and Aghajanian GK (1973b) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571.
5. Carson RE, Channing MA, Der MG, Herscovitch P, and Eckelman W (2002) Scatchard analysis with bolus/infusion administration of [11C]raclopride: amphetamine effects in anesthetized monkeys, in Brain Imaging Using PET (Senda M, Kimura Y and Herscovitch P eds) pp 63-69, Academic Press, San Diego.
6. Doudet DJ, Jivan S, Ruth TJ, and Holden JE (2002) Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 44:198-202.
7. Farde L, Hall H, Ehrin E, and Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science (Wash DC) 231:258-261.
8. Farde L, Hall H, Pauli S, and Halldin C (1995) Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 20:200-208.
9. Gardner B and Strange PG (1998) Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol 124:978-984.
10. George SR, Watanabe M, and Seeman P (1985) Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states. J Neurochem 44:1168-1177.
11. Ginovart N, Farde L, Halldin C, and Swahn CG (1997) Effect of reserpine-induced depletion of synaptic dopamine on [C-11]raclopride binding to D-2-dopamine receptors in the monkey brain. Synapse 25:321-325.
12. Grigoriadis D and Seeman P (1985) Complete conversion of brain D2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J Neurochem 44:1925-1935.
13. Hall H, Halldin C, and Sedvall G (1992) Gpp(NH)p stimulates [3H]raclopride binding to homogenates from human putamen and accumbens. Neurosci Lett 136:79-82.
14. Hall H, Wedel I, and Sallemark M (1988) Effects of temperature on the in vitro binding of 3H-raclopride to rat striatal dopamine-D2 receptors. Pharmacol Toxicol 63:118-121.
15. Hietala J, Nagren K, Lehikoinen P, Ruotsalainen U, and Syvalahti E (1999) Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 19:210-217.
16. Holden JE, Jivan S, Ruth TJ, and Doudet DJ (2002) In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cereb Blood Flow Metab 22:1132-1141.
17. Hwang D, Kegeles LS, and Laruelle M (2000) (-)-N-[(11)C]Propyl- norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol 27:533-539.
18. Hwang DR, Narendran R, Huang Y, Slifstein M, Talbot PS, Sudo Y, Van Berckel BN, Kegeles LS, Martinez D, and Laruelle M (2004) Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates. J Nucl Med 45:338-346.
19. Kohler C, Hall H, Ogren SO, and Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259.
20. Kortekaas R, Maguire RP, Cremers TI, Dijkstra D, van Waarde A, and Leenders KL (2004) In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and implications for the "ceiling effect" in endogenous competition studies with [(11)C]raclopride-a positron emission tomography study in Macaca mulatta. J Cereb Blood Flow Metab 24:531-535.
21. Lahti RA, Mutin A, Cochrane EV, Tepper PG, Dijkstra D, Wikstrom H, and Tamminga CA (1996) Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors. Eur J Pharmacol 301:R11-R13.
22. Laruelle M, Abi-Dargham A, Al-Tikriti MS, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Charney DS, Hoffer PB, and Innis RB (1994a) SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14:453-465.
23. 123I] iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 263:39-51.
24. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, and Bradberry CW (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14.
25. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, and Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
26. Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez D, Kegeles LS, Abi-Dargham A, et al. (2004) In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 52:188-208.
27. Neumeyer JL, Neustadt BR, Oh KH, Weinhardt KK, Boyce CB, Rosenberg FJ, and Teiger DG (1973) Aporphines. 8. Total synthesis and pharmacological evaluation of (±)-apomorphine, (±)-apocodeine, (±)-N-n-propylnorapomorphine and (±)-N-npropylnorapocodeine. J Med Chem 16:1223-1228.
28. Richfield EK, Penney JB, and Young AB (1989) Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience 30:767-777.
29. Roberts DJ and Strange PG (2005) Mechanisms of inverse agonist action at D2 dopamine receptors. Br J Pharmacol 145:34-42.
30. 11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 11:204-219.
31. Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660-672.
32. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
33. Seeman P and Kapur S (2003) Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. Synapse 50:35-40.
34. Seeman P, Niznik HB, Guan HC, Booth G, and Ulpian C (1989) Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86:10156-10160.
35. Seeman P, Tallerico T, Ko F, Tenn C, and Kapur S (2002) Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46:235-239.
36. Seeman P and Van Tol HH (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270.
37. Seeman P, Watanabe M, Grigoriadis D, Tedesco JL, George SR, Svensson U, Nilsson JL, and Neumeyer JL (1985) Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 28:391-399.
38. 2 dopamine receptor. J Biol Chem 257:6351-6361.
39. Slifstein M, Hwang DR, Huang Y, Guo N, Sudo Y, Narendran R, Talbot P, and Laruelle M (2004a) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology 175:274-286.
40. Slifstein M, Hwang DR, Huang Y, Guo NN, Sudo Y, Narendran R, Talbot P, and Laruelle M (2004b) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology 175:274-286.